ID   TGS1_HUMAN              Reviewed;         853 AA.
AC   Q96RS0; A6NJQ5; Q5GH23; Q8TDG9; Q96QU3; Q9H5V3;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 3.
DT   10-MAY-2017, entry version 136.
DE   RecName: Full=Trimethylguanosine synthase;
DE            EC=2.1.1.-;
DE   AltName: Full=CLL-associated antigen KW-2;
DE   AltName: Full=Cap-specific guanine-N2 methyltransferase;
DE   AltName: Full=Hepatocellular carcinoma-associated antigen 137;
DE   AltName: Full=Nuclear receptor coactivator 6-interacting protein;
DE   AltName: Full=PRIP-interacting protein with methyltransferase motif;
DE            Short=PIMT;
DE            Short=PIPMT;
GN   Name=TGS1; Synonyms=HCA137, NCOA6IP, PIMT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH NCOA6, TISSUE
RP   SPECIFICITY, AND VARIANT THR-16.
RC   TISSUE=Liver;
RX   PubMed=11517327; DOI=10.1073/pnas.181347498;
RA   Zhu Y.-J., Qi C., Cao W.-Q., Yeldandi A.V., Rao M.S., Reddy J.K.;
RT   "Cloning and characterization of PIMT, a protein with a
RT   methyltransferase domain, which interacts with and enhances nuclear
RT   receptor coactivator PRIP function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10380-10385(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-16.
RX   PubMed=12200376; DOI=10.1182/blood-2002-02-0513;
RA   Krackhardt A.M., Witzens M., Harig S., Hodi F.S., Zauls A.J.,
RA   Chessia M., Barrett P., Gribben J.G.;
RT   "Identification of tumor-associated antigens in chronic lymphocytic
RT   leukemia by SEREX.";
RL   Blood 100:2123-2131(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-16.
RX   PubMed=12097419; DOI=10.4049/jimmunol.169.2.1102;
RA   Wang Y., Han K.-J., Pang X.-W., Vaughan H.A., Qu W., Dong X.-Y.,
RA   Peng J.-R., Zhao H.-T., Rui J.-A., Leng X.-S., Cebon J., Burgess A.W.,
RA   Chen W.-F.;
RT   "Large scale identification of human hepatocellular carcinoma-
RT   associated antigens by autoantibodies.";
RL   J. Immunol. 169:1102-1109(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 276-853.
RC   TISSUE=Rhabdomyosarcoma;
RA   Behrends U., Gotz C., Mautner J.;
RT   "SEREX-defined rhabdomyosarcoma antigens.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 574-853.
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 629-853.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12032086; DOI=10.1093/emboj/21.11.2736;
RA   Verheggen C., Lafontaine D.L.J., Samarsky D., Mouaikel J.,
RA   Blanchard J.-M., Bordonne R., Bertrand E.;
RT   "Mammalian and yeast U3 snoRNPs are matured in specific and related
RT   nuclear compartments.";
RL   EMBO J. 21:2736-2745(2002).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH CREBBP; EP300 AND PPARBP.
RX   PubMed=11912212; DOI=10.1074/jbc.M201739200;
RA   Misra P., Qi C., Yu S., Shah S.H., Cao W.Q., Rao M.S., Thimmapaya B.,
RA   Zhu Y., Reddy J.K.;
RT   "Interaction of PIMT with transcriptional coactivators CBP, p300, and
RT   PBP differential role in transcriptional regulation.";
RL   J. Biol. Chem. 277:20011-20019(2002).
RN   [10]
RP   INTERACTION WITH EED, AND SUBCELLULAR LOCATION.
RX   PubMed=12943661; DOI=10.1016/S0006-291X(03)01514-6;
RA   Enuenlue I., Papai G., Cserpan I., Udvardy A., Jeang K.-T., Boros I.;
RT   "Different isoforms of PRIP-interacting protein with methyltransferase
RT   domain/trimethylguanosine synthase localize to the cytoplasm and
RT   nucleus.";
RL   Biochem. Biophys. Res. Commun. 309:44-51(2003).
RN   [11]
RP   INTERACTION WITH SMN.
RX   PubMed=12776181; DOI=10.1038/sj.embor.embor863;
RA   Mouaikel J., Narayanan U., Verheggen C., Matera A.G., Bertrand E.,
RA   Tazi J., Bordonne R.;
RT   "Interaction between the small-nuclear-RNA cap hypermethylase and the
RT   spinal muscular atrophy protein, survival of motor neuron.";
RL   EMBO Rep. 4:616-622(2003).
RN   [12]
RP   FUNCTION.
RX   PubMed=16687569; DOI=10.1091/mbc.E06-03-0247;
RA   Lemm I., Girard C., Kuhn A.N., Watkins N.J., Schneider M.,
RA   Bordonne R., Luehrmann R.;
RT   "Ongoing U snRNP biogenesis is required for the integrity of Cajal
RT   bodies.";
RL   Mol. Biol. Cell 17:3221-3231(2006).
RN   [13]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF PHE-655;
RP   THR-673; ASP-696; ASN-704; ASP-719; ASN-731; SER-763; TRP-766; ARG-807
RP   AND ASN-808.
RX   PubMed=18775984; DOI=10.1074/jbc.M806127200;
RA   Hausmann S., Zheng S., Costanzo M., Brost R.L., Garcin D., Boone C.,
RA   Shuman S., Schwer B.;
RT   "Genetic and biochemical analysis of yeast and human cap
RT   trimethylguanosine synthase: functional overlap of 2,2,7-
RT   trimethylguanosine caps, small nuclear ribonucleoprotein components,
RT   pre-mRNA splicing factors, and RNA decay pathways.";
RL   J. Biol. Chem. 283:31706-31718(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; THR-60; SER-154 AND
RP   SER-438, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; THR-60; SER-89;
RP   SER-154 AND SER-438, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85 AND SER-89, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-89, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; SER-85; SER-89;
RP   SER-96; SER-141; TYR-146; SER-154; SER-189; SER-412 AND SER-578, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.21 ANGSTROMS) OF 653-853.
RX   PubMed=19307714; DOI=10.1107/S0907444909003102;
RA   Monecke T., Dickmanns A., Strasser A., Ficner R.;
RT   "Structure analysis of the conserved methyltransferase domain of human
RT   trimethylguanosine synthase TGS1.";
RL   Acta Crystallogr. D 65:332-338(2009).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 618-853 IN COMPLEX WITH
RP   7-METHYLGUANOSINE AND S-ADENOSYL-L-HOMOCYSTEINE, AND MUTAGENESIS OF
RP   SER-763 AND TRP-766.
RX   PubMed=19386620; DOI=10.1093/nar/gkp249;
RA   Monecke T., Dickmanns A., Ficner R.;
RT   "Structural basis for m7G-cap hypermethylation of small nuclear, small
RT   nucleolar and telomerase RNA by the dimethyltransferase TGS1.";
RL   Nucleic Acids Res. 37:3865-3877(2009).
CC   -!- FUNCTION: Catalyzes the 2 serial methylation steps for the
CC       conversion of the 7-monomethylguanosine (m(7)G) caps of snRNAs and
CC       snoRNAs to a 2,2,7-trimethylguanosine (m(2,2,7)G) cap structure.
CC       The enzyme is specific for guanine, and N7 methylation must
CC       precede N2 methylation. Hypermethylation of the m7G cap of U
CC       snRNAs leads to their concentration in nuclear foci, their
CC       colocalization with coilin and the formation of canonical Cajal
CC       bodies (CBs). Plays a role in transcriptional regulation.
CC       {ECO:0000269|PubMed:11517327, ECO:0000269|PubMed:11912212,
CC       ECO:0000269|PubMed:16687569, ECO:0000269|PubMed:18775984}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + m(7)G(5')pppR-RNA =
CC       S-adenosyl-L-homocysteine + m(2,7)G(5')pppR-RNA.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + m(2,7)G(5')pppR-RNA
CC       = S-adenosyl-L-homocysteine + m(2,2,7)G(5')pppR-RNA.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=30 uM for m(7)GDP {ECO:0000269|PubMed:18775984};
CC         KM=5 uM for S-adenosyl-L-methionine
CC         {ECO:0000269|PubMed:18775984};
CC       pH dependence:
CC         Optimum pH is 8.5-9.5. {ECO:0000269|PubMed:18775984};
CC   -!- SUBUNIT: May form homooligomers. Interacts with CREBBP/CBP,
CC       EED/WAIT1, EP300/P300, NCOA6/PRIP, PPARBP/PBP and SMN.
CC       {ECO:0000269|PubMed:11517327, ECO:0000269|PubMed:11912212,
CC       ECO:0000269|PubMed:12776181, ECO:0000269|PubMed:12943661,
CC       ECO:0000269|PubMed:19386620}.
CC   -!- INTERACTION:
CC       Q9Y2X3:NOP58; NbExp=2; IntAct=EBI-949244, EBI-395469;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12943661}.
CC       Nucleus, Cajal body {ECO:0000305|PubMed:12032086}. Nucleus,
CC       nucleolus {ECO:0000269|PubMed:12032086}. Note=A 90 kDa isoform is
CC       found in the nucleus while a 55 kDa isoform is found in the
CC       cytoplasm and colocalizes with the tubulin network.
CC       {ECO:0000269|PubMed:12943661}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. High expression in
CC       heart, skeletal muscle, kidney, liver and placenta.
CC       {ECO:0000269|PubMed:11517327}.
CC   -!- SIMILARITY: Belongs to the methyltransferase superfamily.
CC       Trimethylguanosine synthase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH11999.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15516.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY028423; AAK27730.1; -; mRNA.
DR   EMBL; AF432215; AAL99922.1; -; mRNA.
DR   EMBL; AF286340; AAK83025.1; -; mRNA.
DR   EMBL; AC100817; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY534911; AAT02709.1; -; mRNA.
DR   EMBL; BC011999; AAH11999.1; ALT_INIT; mRNA.
DR   EMBL; AK026648; BAB15516.1; ALT_INIT; mRNA.
DR   CCDS; CCDS34894.1; -.
DR   RefSeq; NP_001304831.1; NM_001317902.1.
DR   RefSeq; NP_079107.6; NM_024831.7.
DR   UniGene; Hs.335068; -.
DR   PDB; 3EGI; X-ray; 2.21 A; A/B/C/D=653-853.
DR   PDB; 3GDH; X-ray; 2.00 A; A/B/C=618-853.
DR   PDBsum; 3EGI; -.
DR   PDBsum; 3GDH; -.
DR   ProteinModelPortal; Q96RS0; -.
DR   SMR; Q96RS0; -.
DR   BioGrid; 125179; 38.
DR   DIP; DIP-49970N; -.
DR   IntAct; Q96RS0; 31.
DR   MINT; MINT-2878093; -.
DR   STRING; 9606.ENSP00000260129; -.
DR   iPTMnet; Q96RS0; -.
DR   PhosphoSitePlus; Q96RS0; -.
DR   BioMuta; TGS1; -.
DR   DMDM; 317373500; -.
DR   EPD; Q96RS0; -.
DR   MaxQB; Q96RS0; -.
DR   PaxDb; Q96RS0; -.
DR   PeptideAtlas; Q96RS0; -.
DR   PRIDE; Q96RS0; -.
DR   DNASU; 96764; -.
DR   Ensembl; ENST00000260129; ENSP00000260129; ENSG00000137574.
DR   GeneID; 96764; -.
DR   KEGG; hsa:96764; -.
DR   UCSC; uc003xsj.5; human.
DR   CTD; 96764; -.
DR   DisGeNET; 96764; -.
DR   GeneCards; TGS1; -.
DR   H-InvDB; HIX0007515; -.
DR   HGNC; HGNC:17843; TGS1.
DR   HPA; HPA025024; -.
DR   HPA; HPA029824; -.
DR   MIM; 606461; gene.
DR   neXtProt; NX_Q96RS0; -.
DR   OpenTargets; ENSG00000137574; -.
DR   PharmGKB; PA162405660; -.
DR   eggNOG; KOG2730; Eukaryota.
DR   eggNOG; ENOG410XRUD; LUCA.
DR   GeneTree; ENSGT00390000018056; -.
DR   HOGENOM; HOG000154561; -.
DR   HOVERGEN; HBG059797; -.
DR   InParanoid; Q96RS0; -.
DR   KO; K14292; -.
DR   OMA; MNTRNKV; -.
DR   OrthoDB; EOG091G0DYO; -.
DR   PhylomeDB; Q96RS0; -.
DR   TreeFam; TF313065; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-191859; snRNP Assembly.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   ChiTaRS; TGS1; human.
DR   EvolutionaryTrace; Q96RS0; -.
DR   GeneWiki; TGS1; -.
DR   GenomeRNAi; 96764; -.
DR   PRO; PR:Q96RS0; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000137574; -.
DR   CleanEx; HS_TGS1; -.
DR   ExpressionAtlas; Q96RS0; baseline and differential.
DR   Genevisible; Q96RS0; HS.
DR   GO; GO:0015030; C:Cajal body; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0030532; C:small nuclear ribonucleoprotein complex; IC:BHF-UCL.
DR   GO; GO:0008173; F:RNA methyltransferase activity; TAS:Reactome.
DR   GO; GO:0071164; F:RNA trimethylguanosine synthase activity; IDA:BHF-UCL.
DR   GO; GO:0036261; P:7-methylguanosine cap hypermethylation; IDA:BHF-UCL.
DR   GO; GO:0009452; P:7-methylguanosine RNA capping; IEA:InterPro.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0022613; P:ribonucleoprotein complex biogenesis; IC:BHF-UCL.
DR   GO; GO:0071167; P:ribonucleoprotein complex import into nucleus; IC:BHF-UCL.
DR   GO; GO:0000387; P:spliceosomal snRNP assembly; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR019012; RNA_cap_Gua-N2-MeTrfase.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   Pfam; PF09445; Methyltransf_15; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Methyltransferase;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   S-adenosyl-L-methionine; Transcription; Transcription regulation;
KW   Transferase.
FT   CHAIN         1    853       Trimethylguanosine synthase.
FT                                /FTId=PRO_0000204468.
FT   REGION      631    846       Sufficient for catalytic activity.
FT   COMPBIAS    611    624       Lys-rich.
FT   BINDING     719    719       S-adenosyl-L-methionine. {ECO:0000250}.
FT   BINDING     766    766       7-methylguanosine.
FT                                {ECO:0000269|PubMed:19386620}.
FT   MOD_RES      55     55       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      60     60       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES      85     85       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      89     89       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      96     96       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     141    141       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     146    146       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     154    154       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     189    189       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     412    412       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     438    438       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES     578    578       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      16     16       I -> T (in dbSNP:rs1818).
FT                                {ECO:0000269|PubMed:11517327,
FT                                ECO:0000269|PubMed:12097419,
FT                                ECO:0000269|PubMed:12200376}.
FT                                /FTId=VAR_024734.
FT   VARIANT     160    160       I -> V (in dbSNP:rs3213971).
FT                                /FTId=VAR_024735.
FT   VARIANT     299    299       P -> S (in dbSNP:rs11986329).
FT                                /FTId=VAR_056241.
FT   VARIANT     511    511       I -> T (in dbSNP:rs10100659).
FT                                /FTId=VAR_024736.
FT   VARIANT     576    576       V -> I (in dbSNP:rs16922259).
FT                                /FTId=VAR_024737.
FT   VARIANT     595    595       T -> A (in dbSNP:rs10109493).
FT                                /FTId=VAR_056242.
FT   VARIANT     754    754       F -> C (in dbSNP:rs7823773).
FT                                /FTId=VAR_024738.
FT   MUTAGEN     655    655       F->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:18775984}.
FT   MUTAGEN     673    673       T->A: Decreases catalytic activity to 13
FT                                percent of wild type.
FT                                {ECO:0000269|PubMed:18775984}.
FT   MUTAGEN     696    696       D->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:18775984}.
FT   MUTAGEN     704    704       N->A: Decreases catalytic activity to 5
FT                                percent of wild type.
FT                                {ECO:0000269|PubMed:18775984}.
FT   MUTAGEN     719    719       D->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:18775984}.
FT   MUTAGEN     731    731       N->A: Decreases catalytic activity to 4
FT                                percent of wild type.
FT                                {ECO:0000269|PubMed:18775984}.
FT   MUTAGEN     763    763       S->A: Decreases catalytic activity to 26
FT                                percent of wild type.
FT                                {ECO:0000269|PubMed:18775984,
FT                                ECO:0000269|PubMed:19386620}.
FT   MUTAGEN     766    766       W->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:18775984,
FT                                ECO:0000269|PubMed:19386620}.
FT   MUTAGEN     807    807       R->A: Decreases catalytic activity to 6
FT                                percent of wild type.
FT                                {ECO:0000269|PubMed:18775984}.
FT   MUTAGEN     808    808       N->A: Decreases catalytic activity to 11
FT                                percent of wild type.
FT                                {ECO:0000269|PubMed:18775984}.
FT   CONFLICT    566    566       Missing (in Ref. 1; AAK27730).
FT                                {ECO:0000305}.
FT   CONFLICT    624    624       N -> T (in Ref. 3; AAK83025).
FT                                {ECO:0000305}.
FT   CONFLICT    628    628       N -> T (in Ref. 3; AAK83025).
FT                                {ECO:0000305}.
FT   CONFLICT    681    681       I -> F (in Ref. 1; AAK27730).
FT                                {ECO:0000305}.
FT   CONFLICT    771    771       Y -> H (in Ref. 2; AAL99922).
FT                                {ECO:0000305}.
FT   HELIX       636    640       {ECO:0000244|PDB:3GDH}.
FT   HELIX       642    644       {ECO:0000244|PDB:3GDH}.
FT   HELIX       645    649       {ECO:0000244|PDB:3GDH}.
FT   HELIX       651    654       {ECO:0000244|PDB:3GDH}.
FT   HELIX       658    660       {ECO:0000244|PDB:3GDH}.
FT   HELIX       666    671       {ECO:0000244|PDB:3GDH}.
FT   HELIX       675    688       {ECO:0000244|PDB:3GDH}.
FT   STRAND      692    696       {ECO:0000244|PDB:3GDH}.
FT   HELIX       703    710       {ECO:0000244|PDB:3GDH}.
FT   STRAND      714    720       {ECO:0000244|PDB:3GDH}.
FT   HELIX       722    734       {ECO:0000244|PDB:3GDH}.
FT   HELIX       738    740       {ECO:0000244|PDB:3GDH}.
FT   STRAND      741    746       {ECO:0000244|PDB:3GDH}.
FT   HELIX       748    751       {ECO:0000244|PDB:3GDH}.
FT   HELIX       752    754       {ECO:0000244|PDB:3GDH}.
FT   STRAND      758    762       {ECO:0000244|PDB:3GDH}.
FT   HELIX       769    773       {ECO:0000244|PDB:3GDH}.
FT   STRAND      774    777       {ECO:0000244|PDB:3GDH}.
FT   TURN        779    781       {ECO:0000244|PDB:3GDH}.
FT   STRAND      782    785       {ECO:0000244|PDB:3EGI}.
FT   HELIX       787    797       {ECO:0000244|PDB:3GDH}.
FT   STRAND      801    806       {ECO:0000244|PDB:3GDH}.
FT   HELIX       811    816       {ECO:0000244|PDB:3GDH}.
FT   STRAND      824    831       {ECO:0000244|PDB:3GDH}.
FT   STRAND      834    842       {ECO:0000244|PDB:3GDH}.
FT   HELIX       843    845       {ECO:0000244|PDB:3EGI}.
SQ   SEQUENCE   853 AA;  96620 MW;  FF670AFBE0979443 CRC64;
     MCCEKWSRVA EMFLFIEERE DCKILCLCSR AFVEDRKLYN LGLKGYYIRD SGNNSGDQAT
     EEEEGGYSCG TAESHDSKGI GLDESELDSE AELMRSMGLP LQFGRITAHK DFEVSMNTRN
     KVKIKKKKHQ KKYLDEIVQE SWRKEYEEDD ILASDDPSSI EQYENTRTYE LQSKKDTETE
     NPPVENTLSP KLEITEKWEK YWNEYGGGLL WQSWQEKHPG QALSSEPWNF PDTKEEWEQH
     YSQLYWYYLE QFQYWEAQGW TFDASQSCDT DTYTSKTEAD DKNDEKCMKV DLVSFPSSPI
     MVDNDSSGTS DKDHSEILDG ISNIKLNSEE VTQSQLDSCT SHDGHQQLSE VSSKRECPAS
     GQSEPRNGGT NEESNSSGNT NTDPPAEDSQ KSSGANTSKD RPHASGTDGD ESEEDPPEHK
     PSKLKRSHEL DIDENPASDF DDSGSLLGFK YGSGQKYGGI PNFSHRQVRY LEKNVKLKSK
     YLDMRRQIKM KNKHIFFTKE SEKPFFKKSK ILSKVEKFLT WVNKPMDEEA SQESSSHDNV
     HDASTSSDSE EQDMSVKKGD DLLETNNPEP EKCQSVSSAG ELETENYERD SLLATVPDEQ
     DCVTQEVPDS RQAETEAEVK KKKNKKKNKK VNGLPPEIAA VPELAKYWAQ RYRLFSRFDD
     GIKLDREGWF SVTPEKIAEH IAGRVSQSFK CDVVVDAFCG VGGNTIQFAL TGMRVIAIDI
     DPVKIALARN NAEVYGIADK IEFICGDFLL LASFLKADVV FLSPPWGGPD YATAETFDIR
     TMMSPDGFEI FRLSKKITNN IVYFLPRNAD IDQVASLAGP GGQVEIEQNF LNNKLKTITA
     YFGDLIRRPA SET
//
